Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 194

1.

Risk of precancer determined by HPV genotype combinations in women with minor cytologic abnormalities.

Gage JC, Schiffman M, Solomon D, Wheeler CM, Gravitt PE, Castle PE, Wentzensen N.

Cancer Epidemiol Biomarkers Prev. 2013 Jun;22(6):1095-101. doi: 10.1158/1055-9965.EPI-12-1455. Epub 2013 Apr 19.

2.

Performance of carcinogenic human papillomavirus (HPV) testing and HPV16 or HPV18 genotyping for cervical cancer screening of women aged 25 years and older: a subanalysis of the ATHENA study.

Castle PE, Stoler MH, Wright TC Jr, Sharma A, Wright TL, Behrens CM.

Lancet Oncol. 2011 Sep;12(9):880-90. doi: 10.1016/S1470-2045(11)70188-7. Epub 2011 Aug 22.

PMID:
21865084
3.

Human papillomavirus type 16 infections and 2-year absolute risk of cervical precancer in women with equivocal or mild cytologic abnormalities.

Castle PE, Solomon D, Schiffman M, Wheeler CM.

J Natl Cancer Inst. 2005 Jul 20;97(14):1066-71.

PMID:
16030304
4.

Performance of HPV DNA testing with hybrid capture 2 in triaging women with minor cervical cytologic abnormalities (ASC-US/LSIL) in Northern Thailand.

Khunamornpong S, Settakorn J, Sukpan K, Srisomboon J, Suprasert P, Siriaunkgul S.

Asian Pac J Cancer Prev. 2014;15(24):10961-6.

5.

HPV genotyping for triage of women with abnormal cervical cancer screening results: a multicenter prospective study.

Nakamura Y, Matsumoto K, Satoh T, Nishide K, Nozue A, Shimabukuro K, Endo S, Nagai K, Oki A, Ochi H, Morishita Y, Noguchi M, Yoshikawa H.

Int J Clin Oncol. 2015 Oct;20(5):974-81. doi: 10.1007/s10147-015-0789-4. Epub 2015 Feb 5.

PMID:
25652908
6.

Risk of precancer and follow-up management strategies for women with human papillomavirus-negative atypical squamous cells of undetermined significance.

Safaeian M, Solomon D, Wacholder S, Schiffman M, Castle P.

Obstet Gynecol. 2007 Jun;109(6):1325-31.

PMID:
17540804
7.

Hierarchical clustering of human papilloma virus genotype patterns in the ASCUS-LSIL triage study.

Wentzensen N, Wilson LE, Wheeler CM, Carreon JD, Gravitt PE, Schiffman M, Castle PE.

Cancer Res. 2010 Nov 1;70(21):8578-86. doi: 10.1158/0008-5472.CAN-10-1188. Epub 2010 Oct 19.

8.

Human papillomavirus testing versus repeat cytology for triage of minor cytological cervical lesions.

Arbyn M, Roelens J, Simoens C, Buntinx F, Paraskevaidis E, Martin-Hirsch PP, Prendiville WJ.

Cochrane Database Syst Rev. 2013 Mar 28;(3):CD008054. doi: 10.1002/14651858.CD008054.pub2. Review.

PMID:
23543559
9.

The influence of type-specific human papillomavirus infections on the detection of cervical precancer and cancer: A population-based study of opportunistic cervical screening in the United States.

Wheeler CM, Hunt WC, Cuzick J, Langsfeld E, Robertson M, Castle PE; New Mexico HPV Pap Registry Steering Committee.

Int J Cancer. 2014 Aug 1;135(3):624-34. doi: 10.1002/ijc.28605. Epub 2014 Apr 15.

10.

Human papillomavirus genotypes in cervical intraepithelial neoplasia grade 3.

Castle PE, Schiffman M, Wheeler CM, Wentzensen N, Gravitt PE.

Cancer Epidemiol Biomarkers Prev. 2010 Jul;19(7):1675-81. doi: 10.1158/1055-9965.EPI-10-0251.

11.

A study of genotyping for management of human papillomavirus-positive, cytology-negative cervical screening results.

Schiffman M, Burk RD, Boyle S, Raine-Bennett T, Katki HA, Gage JC, Wentzensen N, Kornegay JR, Aldrich C, Tam T, Erlich H, Apple R, Befano B, Castle PE.

J Clin Microbiol. 2015 Jan;53(1):52-9. doi: 10.1128/JCM.02116-14. Epub 2014 Oct 22.

14.

Optimal Management Strategies for Primary HPV Testing for Cervical Screening: Cost-Effectiveness Evaluation for the National Cervical Screening Program in Australia.

Simms KT, Hall M, Smith MA, Lew JB, Hughes S, Yuill S, Hammond I, Saville M, Canfell K.

PLoS One. 2017 Jan 17;12(1):e0163509. doi: 10.1371/journal.pone.0163509. eCollection 2017.

15.

Comparison of measurements of human papillomavirus persistence for postcolposcopic surveillance for cervical precancerous lesions.

Gage JC, Schiffman M, Solomon D, Wheeler CM, Castle PE.

Cancer Epidemiol Biomarkers Prev. 2010 Jul;19(7):1668-74. doi: 10.1158/1055-9965.EPI-09-1286.

16.

Evaluation of human papillomavirus testing in primary screening for cervical abnormalities: comparison of sensitivity, specificity, and frequency of referral.

Kulasingam SL, Hughes JP, Kiviat NB, Mao C, Weiss NS, Kuypers JM, Koutsky LA.

JAMA. 2002 Oct 9;288(14):1749-57.

PMID:
12365959
17.

Triage of women with ASCUS and LSIL on Pap smear reports: management by repeat Pap smear, HPV DNA testing, or colposcopy?

Ferris DG, Wright TC Jr, Litaker MS, Richart RM, Lorincz AT, Sun XW, Borgatta L, Buck H, Kramer L, Rubin R.

J Fam Pract. 1998 Feb;46(2):125-34.

PMID:
9487318
18.

Human papillomavirus testing following loop electrosurgical excision procedure identifies women at risk for posttreatment cervical intraepithelial neoplasia grade 2 or 3 disease.

Kreimer AR, Guido RS, Solomon D, Schiffman M, Wacholder S, Jeronimo J, Wheeler CM, Castle PE.

Cancer Epidemiol Biomarkers Prev. 2006 May;15(5):908-14.

19.
20.

Supplemental Content

Support Center